BioCryst Pharmaceuticals, Inc. (BCRX): Price and Financial Metrics

BioCryst Pharmaceuticals, Inc. (BCRX): $5.15

0.14 (+2.79%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

B

Add BCRX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#53 of 363

in industry

BCRX Price/Volume Stats

Current price $5.15 52-week high $9.06
Prev. close $5.01 52-week low $4.82
Day low $4.97 Volume 2,990,300
Day high $5.21 Avg. volume 3,339,847
50-day MA $5.45 Dividend yield N/A
200-day MA $6.30 Market Cap 1.06B

BCRX Stock Price Chart Interactive Chart >

BCRX POWR Grades

  • Value is the dimension where BCRX ranks best; there it ranks ahead of 82.71% of US stocks.
  • BCRX's strongest trending metric is Quality; it's been moving down over the last 26 weeks.
  • BCRX's current lowest rank is in the Stability metric (where it is better than 6.48% of US stocks).

BCRX Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for BCRX is -0.77 -- better than just 5.78% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -1.49 for BIOCRYST PHARMACEUTICALS INC; that's greater than it is for only 5.56% of US stocks.
  • Revenue growth over the past 12 months for BIOCRYST PHARMACEUTICALS INC comes in at 33.18%, a number that bests 86.02% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to BIOCRYST PHARMACEUTICALS INC, a group of peers worth examining would be ASTC, AKTS, ROIV, MIMO, and NWBO.
  • Visit BCRX's SEC page to see the company's official filings. To visit the company's web site, go to www.biocryst.com.

BCRX Valuation Summary

  • In comparison to the median Healthcare stock, BCRX's price/sales ratio is 77.27% higher, now standing at 3.9.
  • BCRX's price/earnings ratio has moved up 4.3 over the prior 243 months.

Below are key valuation metrics over time for BCRX.

Stock Date P/S P/B P/E EV/EBIT
BCRX 2023-12-29 3.9 -3.0 -5.2 -15.4
BCRX 2023-12-28 3.9 -3.0 -5.3 -15.6
BCRX 2023-12-27 4.0 -3.1 -5.4 -15.8
BCRX 2023-12-26 3.9 -3.0 -5.3 -15.6
BCRX 2023-12-22 3.8 -3.0 -5.1 -15.3
BCRX 2023-12-21 3.7 -2.9 -5.0 -15.1

BCRX Growth Metrics

    The 5 year net cashflow from operations growth rate now stands at -99.12%.
  • Its 2 year price growth rate is now at 51.08%.
  • Its year over year net income to common stockholders growth rate is now at 7.41%.
Over the past 15 months, BCRX's revenue has gone up $159,304,000.

The table below shows BCRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 238.44 -170.46 -193.354
2022-06-30 203.607 -161.292 -209.635
2022-03-31 188.034 -158.946 -193.974
2021-12-31 157.17 -142.157 -184.062
2021-09-30 114.028 -154.337 -226.776
2021-06-30 79.136 -169.316 -214.09

BCRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BCRX has a Quality Grade of C, ranking ahead of 64.73% of graded US stocks.
  • BCRX's asset turnover comes in at 0.295 -- ranking 153rd of 682 Pharmaceutical Products stocks.
  • BLCM, VIRX, and GLYC are the stocks whose asset turnover ratios are most correlated with BCRX.

The table below shows BCRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.295 0.901 -0.933
2021-03-31 0.127 0.766 -1.361
2020-12-31 0.083 0.906 -2.051
2020-09-30 0.305 0.922 -3.095
2020-06-30 0.319 0.946 -2.677
2020-03-31 0.368 0.944 -1.858

BCRX Price Target

For more insight on analysts targets of BCRX, see our BCRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $21.27 Average Broker Recommendation 1.58 (Moderate Buy)

BioCryst Pharmaceuticals, Inc. (BCRX) Company Bio


Biocryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. The company was founded in 1986 and is based in Durham, North Carolina.


BCRX Latest News Stream


Event/Time News Detail
Loading, please wait...

BCRX Latest Social Stream


Loading social stream, please wait...

View Full BCRX Social Stream

Latest BCRX News From Around the Web

Below are the latest news stories about BIOCRYST PHARMACEUTICALS INC that investors may wish to consider to help them evaluate BCRX as an investment opportunity.

BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)

– Results published in JACI: In Practice show rapid and sustained reductions in HAE attacks and improved quality of life over 96 weeks of treatment with ORLADEYO –RESEARCH TRIANGLE PARK, N.C., Dec. 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that data from the open-label extension (OLE) of the APeX-2 trial of oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) in patients 12 years and older have be

Yahoo | December 19, 2023

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 16 newly-hired employees stock options to purchase an aggregate of 74,500 shares, and restricted stock units (RSUs) covering an aggregate of 51,050 shares, of BioCryst common stock. The options and RSUs were granted as of November 30, 2023, as inducements material to each employee entering into emplo

Yahoo | December 5, 2023

J.P. Morgan Recommends These 2 ‘Strong Buy’ Stocks With Over 60% Upside Potential

November has a been a good month for the markets, with solid gains on the S&P 500 of 8.5%, bringing the year-to-date haul to ~19%. The question now is, where do we go from here? Don’t go anywhere, rather, stay in the stock market, appears to be the recommendation of JPMorgan’s global investment strategist Madison Faller, who points to three factors that should be supportive going forward. First, the US economy is cooling a bit, enough to ease the threat of overheating; second, the rate of inflat

Yahoo | November 30, 2023

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina

RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older. “We continue to make strides to bring ORLADEYO to patients living with HAE in Latin America in col

Yahoo | November 29, 2023

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Nov. 21, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28th in Miami at 9:35 a.m. ET and the 35th Annual Piper Sandler Healthcare Conference on Wednesday, November 29th in New York at 12:30 p.m. ET. Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst

Yahoo | November 21, 2023

Read More 'BCRX' Stories Here

BCRX Price Returns

1-mo -12.27%
3-mo -14.02%
6-mo -27.26%
1-year -39.84%
3-year -47.04%
5-year -36.73%
YTD -14.02%
2023 -47.82%
2022 -17.11%
2021 85.91%
2020 115.94%
2019 -57.25%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!